NCT03922776 2026-03-18
TILsOV
Centre Oscar Lambret
Phase NA Terminated
Clinical Trials
1,494 trialsNCT04038619 2026-03-18
Fecal Microbiota Transplantation in Treating Immune-Checkpoint Inhibitor Induced-Diarrhea or Colitis in Genitourinary Cancer Patients
M.D. Anderson Cancer Center
Phase 1 Recruiting
NCT06412510 2026-03-18
Prehabilitation for EOC, Fallopian Tube, Primary Peritoneal Carcinoma and Pancreatic Cancer w/ NACT
Case Comprehensive Cancer Center
Phase 1/2 Recruiting
NCT07480785 2026-03-18
TEAS Combined With Triple Antiemetic Drugs to Prevent PONV in High-Risk Patients
Zhejiang University
Phase NA Recruiting
NCT06969833 2026-03-17
BCB-OVAIRE
Centre Oscar Lambret
Phase NA Recruiting
NCT03842982 2026-03-16
CHIPPI
Centre Oscar Lambret
Phase 3 Active not recruiting
NCT05231122 2026-03-16
Pembrolizumab Combined With Bevacizumab With or Without Agonist Anti-CD40 CDX-1140 for the Treatment of Patients With Recurrent Ovarian Cancer
Roswell Park Cancer Institute
Phase 2 Recruiting
NCT05479045 2026-03-16
A Combination Therapy Strategy to Prevent Anti-PD-1 Therapy Resistance in Metastatic Ovarian Cancer Patients
Georgetown University
Phase 2 Not yet recruiting
NCT06412120 2026-03-16
Study Evaluating Safety, Tolerability, and Metabolism of Niraparib
University of Miami
Phase 4 Recruiting
NCT06483048 2026-03-16
MUC1-Activated T Cells for the Treatment of Relapsed and Resistant Ovarian Cancer
Mayo Clinic
Phase 1 Recruiting
NCT07455071 2026-03-16
YS247
Peking University Third Hospital
Phase NA Not yet recruiting
NCT01247779 2026-03-13
ROBO-GYN
Centre Oscar Lambret
Phase NA Completed
NCT07282158 2026-03-13
Adapted Helping Ovarian Cancer Patients Cope Intervention to Address Burnout for Gynecologic Oncology Clinicians
Fred Hutchinson Cancer Center
Phase NA Recruiting
NCT07469709 2026-03-13
PRO-ACTIVE
Fondazione del Piemonte per l'Oncologia
Recruiting
NCT03239145 2026-03-12
Pembrolizumab (Anti-PD-1) and AMG386 (Angiopoietin-2 (Ang-2) in Patients With Advanced Solid Tumor
Dana-Farber Cancer Institute
Phase 1 Completed
NCT07050771 2026-03-12
Comprehensive Multimodal Prehabilitation Alone or With Neoadjuvant Therapy Before Major Cancer Surgery
The Methodist Hospital Research Institute
Phase 2 Recruiting
NCT03586661 2026-03-11
Niraparib and Copanlisib in Treating Patients With Recurrent Endometrial, Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
M.D. Anderson Cancer Center
Phase 1 Active not recruiting
NCT03968406 2026-03-11
Talazoparib and Radiation Therapy in Treating Patients With Locally Recurrent Gynecologic Cancers
M.D. Anderson Cancer Center
Phase 1 Recruiting
NCT05952453 2026-03-11
Newly Diagnosed Stage III/IV Ovarian Cancer, Neoadjuvant Carbo/Taxol/Pembro, Maintenance Olaparib/Pembro
University of Alabama at Birmingham
Phase 2 Recruiting
NCT07465133 2026-03-11
EORTC QOL-OV39
Helios University Hospital Wuppertal
Not yet recruiting
NCT02867956 2026-03-10
Apatinib and Etoposide in Patients With Platinum Resistant or Refractory Ovarian Cancer
Sun Yat-sen University
Phase 2 Completed
NCT03367247 2026-03-10
BOLSTER: Building Out Lifelines for Safety, Trust, Empowerment and Renewal
Dana-Farber Cancer Institute
Phase NA Completed
NCT05494580 2026-03-10
Pamiparib Plus Surufatinib in Patients With Platinum-resistant Ovarian Cancer
Sun Yat-sen University
Phase 1/2 Completed
NCT07460180 2026-03-10
PROOV
The Netherlands Cancer Institute
Phase 1/2 Recruiting
NCT00515372 2026-03-09
Depression Treatment and Screening in Ovarian Cancer Patients
M.D. Anderson Cancer Center
Phase 1 Active not recruiting
NCT02194387 2026-03-09
Energy Balance Interventions in Increasing Physical Activity in Breast Cancer Gene Positive Patients, Lynch Syndrome-Positive Patients, CLL Survivors or High-Risk Family Members
M.D. Anderson Cancer Center
Phase NA Active not recruiting
NCT05162846 2026-03-09
MiGHT
University of Michigan Rogel Cancer Center
Phase NA Completed
NCT05677048 2026-03-09
Feasibility Study: IGNITE-TX (Identifying Individuals for Genetic Testing & Treatment) Intervention
M.D. Anderson Cancer Center
Phase NA Active not recruiting
NCT04454450 2026-03-06
Using Advanced Imaging Studies to Develop a Profile of High-grade Serous Ovarian Cancer
Memorial Sloan Kettering Cancer Center
Phase NA Active not recruiting
NCT06184867 2026-03-06
CATALYST
Rutgers, The State University of New Jersey
Phase NA Completed
NCT07454018 2026-03-06
Iparomlimab/Tuvonralimab + Standard Chemotherapy and Olaparib in Platinum-Sensitive Recurrent Ovarian Cancer
The First Affiliated Hospital of Soochow University
Phase 2 Not yet recruiting
NCT01970722 2026-03-05
Surgery and Chemotherapy With or Without Chemotherapy After Surgery in Treating Patients With Ovarian, Fallopian Tube, Uterine, or Peritoneal Cancer
City of Hope Medical Center
Phase 1 Active not recruiting
NCT04575935 2026-03-05
Minimally Invasive Surgery After Neoadjuvant Chemotherapy for the Treatment of Stage IIIC-IV Ovarian, Primary Peritoneal, or Fallopian Tube Cancer, LANCE Trial
M.D. Anderson Cancer Center
Phase 3 Recruiting
NCT06028932 2026-03-05
A Study of Sacituzumab Govitecan (IMMU-132) in Platinum-resistant Ovarian Cancer Patients
Yale University
Phase 2 Active not recruiting
NCT04091295 2026-03-04
BLESSED: Expanded Access for DNG64-CAR-V for Advanced Pancreatic Cancer, Sarcoma and Carcinoma of Breast
Aveni Foundation
Available
NCT06083844 2026-03-04
Phase II Investigation of Pembrolizumab in Combination With Bevacizumab and Oral Cyclophosphamide in Patients With High Grade Ovarian Cancer and Surgically Documented Minimal Residual Disease After Frontline Therapy
M.D. Anderson Cancer Center
Phase 2 Recruiting
NCT06268665 2026-03-04
Tart Cherry Juice as a Dietary Supplement for the Prevention of Paclitaxel-Induced Neuropathy
University of California, Davis
Phase 2 Recruiting
NCT06321484 2026-03-04
Intraperitoneal Cytokine-Induced Memory Like (CIML) Natural Killer (NK) Cells in Recurrent Ovarian Cancer
Dana-Farber Cancer Institute
Phase 1 Recruiting
NCT06935344 2026-03-03
PROVE
Catholic University of the Sacred Heart
Recruiting
NCT07447050 2026-03-03
Riluzole For Preventing Cognitive Dysfunction in Ca Pts Receiving Chemo (REFOCUS): Pilot Trial
University of California, Irvine
Phase 2 Recruiting
NCT07125209 2026-03-02
Cognitive Impact of Neoadjuvant Chemotherapy for Ovarian Cancer
University of Wisconsin, Madison
Recruiting
NCT07433660 2026-03-02
THRIVE
WellSpan Health
Recruiting
NCT04742075 2026-02-27
DOVACC
Nordic Society of Gynaecological Oncology - Clinical Trials Unit
Phase 2 Active not recruiting
NCT05574673 2026-02-27
HERO
Nordic Society of Gynaecological Oncology - Clinical Trials Unit
Recruiting
NCT06240598 2026-02-27
A Study of Second Look Laparoscopy (SLL) in People With Ovarian Cancer Who Have Completed Their First Course of Chemotherapy
Memorial Sloan Kettering Cancer Center
Phase 2 Active not recruiting
NCT06624878 2026-02-27
Esketamine for Prevention of Depression After Cytoreductive Surgery in Ovarian Cancer
Zhejiang Cancer Hospital
Phase NA Completed
NCT07033819 2026-02-27
Neoadjuvant Treatment of Ovarian Cancer With Fuzuloparib in Combination With Apatinib
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase 2 Recruiting
NCT07439328 2026-02-27
ASTRA Study: Circulating Tumor Cells in Blood of Patients With High-Grade Serous Ovarian Cancer
Institute of Oncology Ljubljana
Phase NA Completed
NCT07440290 2026-02-27
DETERMINE
Cancer Research UK
Phase 2/3 Not yet recruiting
NCT03943173 2026-02-25
Olaparib in Treating Patients With Newly Diagnosed BRCA-Mutant Ovarian, Primary Peritoneal, or Fallopian Cancer Before Surgery
M.D. Anderson Cancer Center
Phase EARLY_PHASE1 Active not recruiting